Home » Stocks » PLSE

Pulse Biosciences, Inc. (PLSE)

Stock Price: $26.94 USD 2.08 (8.37%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 682.70M
Revenue (ttm) n/a
Net Income (ttm) -49.89M
Shares Out 25.22M
EPS (ttm) -2.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $26.94
Previous Close $24.86
Change ($) 2.08
Change (%) 8.37%
Day's Open 24.66
Day's Range 24.69 - 28.86
Day's Volume 185,455
52-Week Range 5.23 - 28.86

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 4 days ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™)...

Business Wire - 1 week ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse StimulationTM (NPS™...

Business Wire - 1 month ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) ...

Business Wire - 1 month ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that a scie...

Business Wire - 2 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to p...

Seeking Alpha - 2 months ago

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financi...

Business Wire - 2 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will re...

Business Wire - 3 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that clinic...

Business Wire - 3 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA Invest...

Business Wire - 3 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced the receip...

Business Wire - 4 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

Business Wire - 4 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

Seeking Alpha - 5 months ago

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

Business Wire - 5 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

Business Wire - 5 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

Business Wire - 6 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS™) technology, today announced that th...

Seeking Alpha - 8 months ago

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 9 months ago

Pulse Biosciences, Inc. (PLSE) Darrin Uecker on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Pulse Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 1 year ago

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Pulse BioSciences is the second instance Bob Duggan has taken the helm of a biotech that has fallen flat in an attempt to reinvigorate it.

About PLSE

Pulse Biosciences operates as a novel bioelectric medicine company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
May 18, 2016
CEO
Darrin R. Uecker
Employees
82
Stock Exchange
NASDAQ
Ticker Symbol
PLSE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for PLSE stock is "Buy" and the 12-month stock price forecast is 16.00.

Price Target
$16.00
Analyst Consensus: Buy